Multicenter, open-label, post-authorization safety study (PASS) of elsulfavirine (Elpida (R)) used in the first-line therapy for HIV-1 infected patients added to standard ART (NNRTI plus two NRTIs)

E. Yakubova,A. Kravchenko, T. Shimonova, T. Bessarab,N. Sizova, E. Stepanova,A. Pokrovskaya, U. Kuimova,A. Kuznetsova, M. Radzikhovskaya, L. Pozdnyakova, Y. Ulyanova,D. Gusev,A. Yakovlev, A. Kovelenov, E. Inozemtseva, S. Baranovsky, R. Arsienko, J. Remeeva, S. Corritori, N. Savchuk, I. Dukes, A. Weichert, D. Richman,R. Murphy

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2020）

Cited 0|Views12

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined